Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...

This was the stock's third consecutive day of gains.

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

A member of the IBD Big Cap 20, Vertex is a top stock to consider after impressive growth last year. VERX stock could present ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...